CCTC Transplant Outcomes Research and Evidence-Based Practice — Questions and Answers
Question 1: SRTR (Scientific Registry of Transplant Recipients) program-specific reports primarily enable transplant coordinators and programs to do which of the following?
- Access individually identifiable patient records for peer review purposes
- Submit organ offers directly to recipient candidates, bypassing DonorNet
- Compare their program's risk-adjusted outcomes against national expected outcomes benchmarks (Correct answer)
- Track real-time donor hormone management protocols at other centers
Correct answer: Compare their program's risk-adjusted outcomes against national expected outcomes benchmarks
SRTR program-specific reports provide publicly available, risk-adjusted outcome data (graft survival, patient survival, wait times) for each transplant program compared to national expected outcomes. These reports are a primary tool for transplant coordinators and quality teams to identify performance gaps, benchmark against peers, and drive targeted quality improvement initiatives.
Question 2: A transplant center's 1-year kidney graft survival rate is flagged as significantly below the SRTR expected value. Applying a PDCA (Plan-Do-Check-Act) quality improvement cycle, what should happen FIRST?
- Immediately change the immunosuppression protocol based on a recent journal article
- Analyze outcomes data to identify root causes of graft loss before planning any intervention (Plan phase) (Correct answer)
- Report the deficit to the state health department and suspend new listings
- Implement a new patient education program to address non-adherence
Correct answer: Analyze outcomes data to identify root causes of graft loss before planning any intervention (Plan phase)
PDCA begins with the Plan phase: systematic data analysis to identify root causes of the performance gap. Implementing changes without root cause analysis (jumping to 'Do') risks costly and potentially harmful interventions that miss the actual problem. The specific cause (e.g., rejection, surgical complications, infection, non-adherence) determines the appropriate intervention.
Question 3: A study comparing tacrolimus to cyclosporine for prevention of acute rejection reports a p-value of 0.03. What is the correct interpretation of this p-value?
- There is a 3% absolute reduction in rejection risk with tacrolimus
- The study has 97% statistical power to detect this difference
- There is a 3% probability of observing results this extreme (or more extreme) if there were truly no difference between the drugs (Correct answer)
- The result is clinically significant and should immediately change practice
Correct answer: There is a 3% probability of observing results this extreme (or more extreme) if there were truly no difference between the drugs
A p-value of 0.03 means: if the null hypothesis (no difference between drugs) were true, there would be only a 3% chance of observing results this extreme by chance alone. A p-value does not measure effect size, clinical importance, or the probability that the null hypothesis is true. Statistical significance (p<0.05) does not automatically equal clinical significance.
Question 4: When reading a clinical trial on a novel induction immunosuppression agent with a primary endpoint of 'biopsy-proven acute rejection at 12 months,' which is the most important limitation for a transplant coordinator to recognize?
- Biopsy-proven rejection is too subjective to be a scientifically valid endpoint
- The 12-month timeframe may not capture late rejection, chronic allograft nephropathy, or long-term graft survival outcomes (Correct answer)
- Induction agents are only used in kidney transplant and results cannot be generalized
- Acute rejection at 12 months is no longer considered clinically relevant
Correct answer: The 12-month timeframe may not capture late rejection, chronic allograft nephropathy, or long-term graft survival outcomes
While 12-month biopsy-proven acute rejection is a validated and commonly used surrogate endpoint, it may not predict long-term outcomes like 5- or 10-year graft survival. Chronic rejection, calcineurin inhibitor nephrotoxicity, malignancy, and metabolic side effects emerge over longer time horizons. Coordinators must critically assess whether short-term surrogate endpoints align with patient-centered long-term outcomes.
Question 5: When a transplant program's outcomes are flagged by the SRTR as significantly below expected thresholds for two consecutive reporting periods, which oversight body reviews the program under the UNOS/OPTN membership framework?
- The Joint Commission's Transplant Accreditation Committee
- The UNOS/OPTN Membership and Professional Standards Committee (MPSC) (Correct answer)
- The state department of health transplant licensing board
- The hospital's internal quality assurance department exclusively
Correct answer: The UNOS/OPTN Membership and Professional Standards Committee (MPSC)
Under OPTN bylaws, programs with outcomes below expected thresholds are reviewed by the Membership and Professional Standards Committee (MPSC), which can require corrective action plans, enhanced monitoring, or in extreme cases recommend membership actions. This is separate from — and in addition to — CMS oversight and Joint Commission accreditation review.
Question 6: A transplant center wants to evaluate whether a new electronic reminders intervention reduces immunosuppressant non-adherence. Which study design would provide the highest level of evidence?
- A retrospective chart review comparing adherence before and after implementing the intervention
- A case series of 20 non-adherent patients who received the intervention
- A randomized controlled trial (RCT) assigning patients to electronic reminders versus usual care (Correct answer)
- An expert consensus statement from a transplant society committee
Correct answer: A randomized controlled trial (RCT) assigning patients to electronic reminders versus usual care
The RCT provides the highest level of evidence by randomly assigning patients to intervention or control groups, minimizing selection bias and confounding that plague observational designs. In transplant research, RCTs are often challenging to conduct due to small populations and ethical constraints, but they remain the gold standard for evaluating interventions. Registry-based observational studies are common but carry inherent confounding risk.
CCTC Transplant Outcomes Research and Evidence-Based Practice
SRTR (Scientific Registry of Transplant Recipients) program-specific reports primarily enable transplant coordinators and programs to do which of the following?